UK markets close in 2 hours 3 minutes

Altimmune, Inc. (0A4C.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
8.01-0.20 (-2.50%)
As of 08:11AM BST. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.20
52-week change 3-1.07%
S&P500 52-week change 328.04%
52-week high 314.82
52-week low 32.12
50-day moving average 310.37
200-day moving average 35.31

Share statistics

Avg vol (3-month) 354.66k
Avg vol (10-day) 315.99k
Shares outstanding 5N/A
Implied shares outstanding 6N/A
Float 870.34M
% held by insiders 10.78%
% held by institutions 163.24%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)-535,879.98%

Management effectiveness

Return on assets (ttm)-29.48%
Return on equity (ttm)-54.46%

Income statement

Revenue (ttm)410k
Revenue per share (ttm)0.01
Quarterly revenue growth (yoy)-76.20%
Gross profit (ttm)N/A
EBITDA -88.09M
Net income avi to common (ttm)-92.77M
Diluted EPS (ttm)-2.39
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)182.02M
Total cash per share (mrq)2.57
Total debt (mrq)552k
Total debt/equity (mrq)0.32%
Current ratio (mrq)16.55
Book value per share (mrq)2.44

Cash flow statement

Operating cash flow (ttm)-72.76M
Levered free cash flow (ttm)-45.06M